 |
 Video: What is a Stock Split?
|
|
|
| Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. According to our BIIB split history records, Biogen has had 0 splits. | |
|
Biogen (BIIB) has 0 splits in our BIIB split history database.
Looking at the BIIB split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Biogen shares, starting with a $10,000 purchase of BIIB, presented on a split-history-adjusted basis factoring in the complete BIIB split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/29/2014 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$290.84 |
|
| End price/share: |
$202.46 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-30.39% |
|
| Average Annual Total Return: |
-3.56% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$6,960.09 |
|
| Years: |
10.00 |
|
|
|
|
|
